Travere Therapeutics amends 2018 Equity Incentive Plan approved by stockholders
Travere Therapeutics' Board amended its 2018 Equity Incentive Plan on March 29, 2026, with stockholder approval on May 19, 2026, as the successor to prior equity plans. The plan provides stock awards including options, RSUs, and performance awards to employees, directors, and consultants.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day